ACC-001

OBJECTIVES Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid- beta therapeutic vaccine, was… Expand

Both active and passive anti-β-amyloid (Aβ) immunotherapies have been reported to clear brain Aβ deposits in transgenic mouse… Expand

Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy that aims to reduce brain… Expand

BACKGROUND ACC-001 is an investigational therapeutic vaccine designed to elicit antibodies against the N-terminal peptide 1-7 of… Expand

BACKGROUND Vanutide Cridificar (ACC-001), a novel investigational immunotherapeutic vaccine designed to elicit antibodies against… Expand

OBJECTIVE Multiple lines of evidence indicate that pathological accumulation of amyloid beta (Aβ) peptide in the brain is linked… Expand

Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated… Expand

PURPOSE OF REVIEW We reviewed clinical trials on active and passive anti-β-amyloid (Aβ) immunotherapy for the treatment of… Expand

We would like to clarify and update information in the review article by Wilcock and Colton recently published in JAD [1]. In… Expand

Background: In a phase 2a clinical trial of AN1792 (Study 201), a potential immunotherapeutic agent for use in Alzheimer’s… Expand